NYSE: IFFInternational Flavors & Fragrances
International Flavors & Fragrances Q3 2026 Results: Net Loss $55 Million on Revenue of $1.94 Billion
- US stocks
- Earnings
- Materials

International Flavors & Fragrances (NYSE: IFF) reported third quarter 2026 GAAP net sales of $1.94 billion and a GAAP net loss attributable to IFF shareholders of $55.0 million, and it said on 3 Nov 2026. Diluted EPS was a GAAP loss of $0.22 per share, and adjusted EPS excluding amortization, a company-defined measure, was $0.83.
Key highlights
- Net sales (GAAP): $1.94 billion, up 3.9% YoY and down 0.6% QoQ
- Operating income (GAAP): $160.0 million, down 16.2% YoY and up 1.3% QoQ
- Net loss (GAAP): $55.0 million, against net income of $40.0 million a year earlier
- Adjusted EPS excluding amortization (company-defined): $0.83 per share, against $0.76 a year earlier
Summary
| Particulars | Q3 2026 | Q3 2025 | YoY | Q2 2026 | QoQ |
|---|---|---|---|---|---|
| Revenue | 1,942.0 | 1,869.0 | +3.9% | 1,954.0 | -0.6% |
| 160.0 | 191.0 | -16.2% | 158.0 | +1.3% | |
| Operating margin | 8.24% | 10.22% | -1.98 pp | 8.09% | +0.15 pp |
| -55.0 | 40.0 | n/a | 50.0 | n/a | |
| Net income margin | -2.83% | 2.14% | -4.97 pp | 2.56% | -5.39 pp |
| Diluted EPS ($) | -0.22 | 0.16 | n/a | 0.20 | n/a |
Figures are in $ million except EPS; YoY compares with Q3 2025 and QoQ with Q2 2026. Q3 2026 is the three months to 30 Sep 2026, from the company's release. Earlier quarters are checked against the company's SEC XBRL filings. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.
The table shows net sales of $1,942.0 million, up 3.9% from $1,869.0 million a year earlier and down 0.6% from $1,954.0 million in the previous quarter. Operating income was $160.0 million, an operating margin of 8.2% against 10.2% a year earlier, 2.0 percentage points lower.
The table's diluted EPS includes discontinued operations; the release gives $(0.50) per diluted share from continuing operations.
Adjusted figures exclude items the company names
Adjusted operating EBITDA, a company-defined non-GAAP measure, was $403 million, against $384 million a year earlier. The company says it excludes depreciation and amortization, interest, other expense and items such as goodwill impairment, restructuring, held-for-sale losses, divestiture, strategic initiative and regulatory costs.
The release ties the $236 million loss on assets classified as held for sale to the Botanicals & Food Enhancements disposal group and the CitraSource business.
Taste and Scent sales rose on a comparable basis
Taste sales were $687 million, with comparable currency neutral sales up 6%, and adjusted operating EBITDA of $128 million, a margin of 18.6%. Scent sales were $689 million, up 6% on the same basis, with adjusted operating EBITDA of $139 million, a margin of 20.2%.
Health & Biosciences sales were $566 million, up 1% on a comparable currency neutral basis. The company said its Food Biosciences and Grain Processing businesses grew by mid-single digits, which outweighed a fall in Health. Its adjusted operating EBITDA was $136 million, a 24.0% margin.
Guidance for 2026 has a higher low end
The company now expects full-year 2026 sales of $7.5 billion to $7.6 billion, against $7.4 billion to $7.6 billion previously, and adjusted operating EBITDA of $1.55 billion to $1.60 billion, against $1.53 billion to $1.60 billion previously.
Measured on continuing operations, the company's new range for comparable currency neutral sales growth is 3% to 4%, against 2% to 4% previously, and for comparable currency neutral adjusted operating EBITDA growth it is 5% to 8%, against 4% to 8%. The company said it expects fourth-quarter profitability to be softer, particularly in Health & Biosciences, and linked this to higher costs and reinvestments to strengthen the business.
Inference
The average diluted share count was 253 million, against 257 million a year earlier. Treasury stock purchases were $584 million in the first nine months, and cash dividends paid were $306 million, the same as a year earlier. The company said it recently completed its $500 million accelerated share repurchase program.
The release does not state a declared dividend, full-year GAAP guidance or any remaining repurchase authorisation. The next dated step it gives is the Food Ingredients divestiture, which the company said is on track to close by the end of the second quarter 2027.
Filed with the US SEC on . Reference: Original filing (SEC)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

